Priority Date: 17.06.10 (US 20100355845P)

PIPERIDINYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES

  • Application ID: EP11725116
  • Status: APPLICATION DEEMED TO BE WITHDRAWN

Applicant

Technology company logo small
Technology Company

Attorney

no operation time available
1 office
Technology Company

Specialization

This EP application has the IPC class A61 (MEDICAL OR VETERINARY SCIENCE; HYGIENE) and C07 (ORGANIC CHEMISTRY). Novartis Pharma AG is specialized in the combination A61 and C07. We found, that TransMIT GmbH, Kailuweit & Uhlemann, Lederer Keller Patentanwälte Partnerschaft mbB, Vossius & Partner Patentanwälte Rechtsanwälte mbB, df-mp Dörries Frank-Molnia & Pohlman, Patentanwälte Rechtsanwälte PartG mbB and 230 others are specialized in all of these IPC classes as well. For a similar patent, they might be a good choice.

Timeline

  • 17.06.2010 - Priority Date (US 20100355845P)
  • 22.12.2011 - Publication A1 (WO2011157793)
  • 24.04.2013 - Publication A1 (EP2582681)